Biotech · Private company
PhaseBio Pharmaceuticals Inc.
Track this companyFree. Adds PhaseBio Pharmaceuticals Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- Low Dose (10 mg) ControlPhase 2 · Acute Respiratory Distress SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- PB1046 InjectionPhase 2 · Heart FailureClinicalTrials.gov · fetched Nov 12, 2026
- Pemziviptadil (PB1046)Phase 2 · Acute Respiratory Distress SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- Pemziviptadil (PB1046)Phase 2 · Pulmonary Arterial HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- Pemziviptadil (PB1046) InjectionPhase 2 · Pulmonary Arterial HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- PB1046 Subcutaneous InjectionPhase 1 · Pulmonary Arterial HypertensionClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).PHASE2 · TERMINATED · started Jul 15, 2020ClinicalTrials.gov NCT04433546 · fetched Nov 12, 2026
- Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004PHASE2 · TERMINATED · started Apr 10, 2019ClinicalTrials.gov NCT03795428 · fetched Nov 12, 2026
- Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAHPHASE2 · TERMINATED · started Jul 15, 2018ClinicalTrials.gov NCT03556020 · fetched Nov 12, 2026
- A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAHPHASE1 · COMPLETED · started Oct 20, 2017ClinicalTrials.gov NCT03315507 · fetched Nov 12, 2026
- Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEFPHASE2 · COMPLETED · started Jun 1, 2016ClinicalTrials.gov NCT02808585 · fetched Nov 12, 2026